source
- Definium Therapeutics clinches third phase-3 win for LSD anxiety drug, eyes FDA filingDefinium Therapeutics reported another successful phase 3 trial of its LSD‑based anxiety treatment, DT120 ODT. The Panorama study enrolled 245 patients and compared a 100 µg dose of DT120 with pla…
- FDA signals openness to innovative approaches for psychedelic drug developmentFDA officials said the agency is open to novel, innovative approaches to the clinical development of psychedelic drugs, citing the worsening mental health crisis in the United States. The agency’s…